The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy
There is an urgent need to develop new combination therapies beyond existing surgery, radio‐ and chemo‐therapy, perhaps initially combining chemotherapy with the targeting specificities of immunotherapy. For this, strategies to limit inflammation and immunosuppression and evasion in the tumour micro...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Published: |
Wiley
2017
|
| Subjects: |
| _version_ | 1804072419467460608 |
|---|---|
| author | Moore, Colin Kosgodage, Uchini S. Lange, Sigrun Inal, Jameel |
| author_facet | Moore, Colin Kosgodage, Uchini S. Lange, Sigrun Inal, Jameel |
| author_sort | Moore, Colin |
| collection | LMU |
| description | There is an urgent need to develop new combination therapies beyond existing surgery, radio‐ and chemo‐therapy, perhaps initially combining chemotherapy with the targeting specificities of immunotherapy. For this, strategies to limit inflammation and immunosuppression and evasion in the tumour microenvironment are also needed. To devise effective new immunotherapies we must first understand tumour immunology, including the roles of T cells, macrophages, myeloid suppressor cells and of exosomes and microvesicles (EMVs) in promoting angiogenesis, tumour growth, drug resistance and metastasis. One promising cancer immunotherapy discussed uses cationic liposomes carrying tumour RNA (RNA‐lipoplexes) to provoke a strong anti‐viral‐like (cytotoxic CD8+) anti‐tumour immune response. Mesenchymal stem cell‐derived EMVs, with their capacity to migrate towards inflammatory areas including solid tumours, have also been used. As tumour EMVs clearly exacerbate the tumour microenvironment, another therapy option could involve EMV removal. Affinity‐based methods to deplete EMVs, including an immunodepletion, antibody‐based affinity substrate, are therefore considered. Finally EMV and exosome‐mimetic nanovesicles (NVs) delivery of siRNA or chemotherapeutic drugs that target tumours using peptide ligands for cognate receptors on the tumour cells are discussed. We also touch upon the reversal of drug efflux in EMVs from cancer cells which can sensitize cells to chemotherapy. The use of immunotherapy in combination with the advent of EMVs provides potent therapies to various cancers. |
| first_indexed | 2024-07-09T03:58:51Z |
| format | Article |
| id | oai:repository.londonmet.ac.uk:5146 |
| institution | London Metropolitan University |
| last_indexed | 2024-07-09T03:58:51Z |
| publishDate | 2017 |
| publisher | Wiley |
| record_format | eprints |
| spelling | oai:repository.londonmet.ac.uk:51462020-03-18T11:22:28Z http://repository.londonmet.ac.uk/5146/ The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy Moore, Colin Kosgodage, Uchini S. Lange, Sigrun Inal, Jameel 610 Medicine & health There is an urgent need to develop new combination therapies beyond existing surgery, radio‐ and chemo‐therapy, perhaps initially combining chemotherapy with the targeting specificities of immunotherapy. For this, strategies to limit inflammation and immunosuppression and evasion in the tumour microenvironment are also needed. To devise effective new immunotherapies we must first understand tumour immunology, including the roles of T cells, macrophages, myeloid suppressor cells and of exosomes and microvesicles (EMVs) in promoting angiogenesis, tumour growth, drug resistance and metastasis. One promising cancer immunotherapy discussed uses cationic liposomes carrying tumour RNA (RNA‐lipoplexes) to provoke a strong anti‐viral‐like (cytotoxic CD8+) anti‐tumour immune response. Mesenchymal stem cell‐derived EMVs, with their capacity to migrate towards inflammatory areas including solid tumours, have also been used. As tumour EMVs clearly exacerbate the tumour microenvironment, another therapy option could involve EMV removal. Affinity‐based methods to deplete EMVs, including an immunodepletion, antibody‐based affinity substrate, are therefore considered. Finally EMV and exosome‐mimetic nanovesicles (NVs) delivery of siRNA or chemotherapeutic drugs that target tumours using peptide ligands for cognate receptors on the tumour cells are discussed. We also touch upon the reversal of drug efflux in EMVs from cancer cells which can sensitize cells to chemotherapy. The use of immunotherapy in combination with the advent of EMVs provides potent therapies to various cancers. Wiley 2017-03-16 Article PeerReviewed Moore, Colin, Kosgodage, Uchini S., Lange, Sigrun and Inal, Jameel (2017) The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy. International Journal of Cancer, 141 (3). pp. 428-436. ISSN 0020-7136 10.1002/ijc.30672 |
| spellingShingle | 610 Medicine & health Moore, Colin Kosgodage, Uchini S. Lange, Sigrun Inal, Jameel The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy |
| title | The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy |
| title_full | The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy |
| title_fullStr | The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy |
| title_full_unstemmed | The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy |
| title_short | The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy |
| title_sort | emerging role of exosome and microvesicle emv based cancer therapeutics and immunotherapy |
| topic | 610 Medicine & health |
| work_keys_str_mv | AT moorecolin theemergingroleofexosomeandmicrovesicleemvbasedcancertherapeuticsandimmunotherapy AT kosgodageuchinis theemergingroleofexosomeandmicrovesicleemvbasedcancertherapeuticsandimmunotherapy AT langesigrun theemergingroleofexosomeandmicrovesicleemvbasedcancertherapeuticsandimmunotherapy AT inaljameel theemergingroleofexosomeandmicrovesicleemvbasedcancertherapeuticsandimmunotherapy AT moorecolin emergingroleofexosomeandmicrovesicleemvbasedcancertherapeuticsandimmunotherapy AT kosgodageuchinis emergingroleofexosomeandmicrovesicleemvbasedcancertherapeuticsandimmunotherapy AT langesigrun emergingroleofexosomeandmicrovesicleemvbasedcancertherapeuticsandimmunotherapy AT inaljameel emergingroleofexosomeandmicrovesicleemvbasedcancertherapeuticsandimmunotherapy |